Chronic hepatitis B

Hepatitis B is caused by a small DNA virus with a large talent for persistence. It infects liver cells and installs its genetic material in their nuclei as a durable template — cccDNA — that current medicines suppress but do not remove, which is why “control” rather than “eradication” frames most treatment conversations. The virus itself does little direct damage; the injury comes from the immune system’s long campaign against infected cells. Decades of that low-grade warfare, in some carriers, lay down scar tissue until the liver’s architecture fails — cirrhosis — and the chronic cycle of injury and regeneration raises the risk of hepatocellular carcinoma, the main form of primary liver cancer. Uniquely among the causes of liver cancer, HBV can produce tumours even before cirrhosis develops, which shapes the surveillance rules described below.

Age at infection decides almost everything about the natural history. Infected as adults, most immune systems win: the illness may be noticeable or silent, but the great majority clear the virus and keep lifelong immunity, with fewer than roughly one in twenty becoming chronic carriers. Infected at birth or in the first years of life — the common story in the high-prevalence regions of East and Southeast Asia and sub-Saharan Africa, and among families from those regions everywhere — the immune system tolerates the virus for years, and chronic infection becomes the rule rather than the exception. That inversion explains why hepatitis B runs in families without being genetic, why screening the family of every diagnosed carrier matters, and why the birth-dose vaccine — given within twenty-four hours of delivery — is the single most consequential intervention in the field.

Chronic infection is not one state but a sequence of phases — the virus abundant but the liver quiet; the immune system engaging and the liver inflamed; a low-activity carrier state; sometimes reactivation — and treatment decisions are anchored to the phase, not the label. Two travelling companions complicate a minority of cases: hepatitis D, a defective virus that can only infect people who already carry HBV and accelerates injury markedly; and co-infection with HIV or hepatitis C, each changing management enough that every new diagnosis is screened for all three.

The scale of the disease frames everything written about it: WHO estimates some 250–300 million people live with chronic hepatitis B, most unaware, making it one of medicine’s largest diagnosed-versus-undiagnosed gaps. That is why guidance leans so hard on testing — and why a page like this one treats “get tested, get linked to care” as its most useful sentence. For the individual reader the statistics compress usefully: found and followed, this is a manageable lifelong condition with a near-normal life expectancy in modern cohorts; unfound, it is the world’s leading driver of liver cancer. The difference is a blood test.

The defining symptom of chronic hepatitis B is the absence of symptoms. Most carriers feel well for decades — the virus does not announce itself, the inflamed liver rarely hurts, and energy is normal or near it. This silence is the clinical problem: without screening, the first “symptom” of thirty silent years can be a complication of cirrhosis or a liver cancer already grown. The corollary is written across every guideline: hepatitis B is found by testing people at risk, not by waiting for them to feel ill. The test itself is a single blood draw, widely available and inexpensive; results return in days; and a negative in an unvaccinated person is the natural moment to vaccinate — the appointment that closes the question for life.

When symptoms do occur in uncomplicated chronic infection, they are vague and easily attributed elsewhere: fatigue that fluctuates, mild right-upper-abdominal discomfort, poor appetite, nausea. Flares — periods when immune attack intensifies — can feel like an acute hepatitis: marked tiredness, aching, nausea, dark urine and jaundice; flares also happen when antivirals are stopped abruptly or when immunity is suppressed by other treatment, both avoidable circumstances discussed later.

The louder symptoms belong to the complications. As cirrhosis decompensates: swelling of the abdomen with fluid (ascites), swollen ankles, vomiting blood or passing black stools from varices, easy bruising, confusion and sleep reversal from encephalopathy, deepening jaundice, muscle wasting. From liver cancer: often nothing early — the reason surveillance exists — then weight loss, right-sided pain, a mass, or sudden decompensation of previously stable cirrhosis. Any of these in a known carrier reframes the situation entirely and belongs in specialist hands that week, not that quarter.

Hepatitis B spreads through blood and body fluids, and the routes that matter differ by region. Where the virus is common, the dominant route is from mother to baby at birth, and between young children in close household contact — the routes the birth-dose vaccine and universal childhood immunisation were designed to close. Where the virus is rarer, adult routes dominate: sexual transmission; sharing of needles and injecting equipment; unsafe medical, dental or cosmetic procedures with inadequately sterilised instruments — including, in some settings, tattooing, piercing and traditional practices; needlestick injuries in healthcare work; and sharing of razors or toothbrushes that carry invisible blood. Screened blood supplies have made transfusion transmission rare wherever screening is universal, a caveat with historical weight for people transfused decades ago.

Just as important is the negative list, because carriers suffer needless isolation. Hepatitis B does NOT spread through food or water, shared meals, cooking, kissing on the cheek, hugging, coughing, sneezing, breastfeeding (with standard newborn immunisation), mosquitoes, toilets or swimming pools. A carrier can cook for a family, share a classroom and an office, and pose no risk through any ordinary contact. Household members and sexual partners — the genuinely exposed group — are protected by testing and vaccination, which every guideline recommends and which turns the household question from anxiety into a checklist. One inherited-looking pattern deserves decoding: when several siblings carry the virus, the shared source is almost always perinatal or early-childhood exposure decades ago, not genetics — and the same checklist (test, vaccinate the negative, monitor the positive) resolves an entire extended family in one clinic season, something hepatology services in high-prevalence communities organise deliberately.

The virus is not inherited in any genetic sense; families share it through birth and early childhood exposure. That distinction carries hope: vaccination interrupts the chain completely, and a carrier mother with modern care — antivirals in late pregnancy when viral load is high, plus birth-dose vaccine and immunoglobulin for the newborn — has an overwhelming likelihood of an uninfected child.

Risk factors for having chronic hepatitis B largely mean birth and early life in — or family origins in — regions where the virus circulates widely: much of East and Southeast Asia, sub-Saharan Africa, the Pacific islands, parts of the Middle East, the Mediterranean and Eastern Europe. Household contact with a carrier, birth to a carrier mother, unvaccinated healthcare exposure, injecting drug use, multiple sexual partners without vaccination, men who have sex with men, dialysis, and historical transfusion or procedures in low-screening settings complete the list. WHO and national bodies now frame testing expansively — many recommend at least one lifetime test for all adults — because the treatable disease is so often silent.

Risk factors for a worse course, in someone already infected, are a separate list worth knowing: co-infection with hepatitis D, C or HIV; heavy alcohol use, which multiplies rather than adds to the liver injury; metabolic fatty liver disease alongside; male sex and older age; a family history of liver cancer; and high sustained viral loads over years. Most of these are exactly the levers that management pulls — alcohol, co-infections, viral load — which is why specialist follow-up changes trajectories rather than merely observing them.

And the reassurance list, cleared explicitly: sharing meals, cups and cutlery; cooking for others; swimming pools; mosquito bites; sweat and tears; ordinary workplace and school contact — none transmits hepatitis B. Carriers have been excluded from kitchens, pools and classrooms on folklore in many countries; the virology has been settled for decades, and this platform states it without hedging.

Chronic hepatitis B moves through recognisable phases, defined by three measurements together: e-antigen status, viral load (HBV DNA) and liver inflammation (ALT). Treatment decisions hang on the phase — which can change over time in both directions, the reason follow-up never really ends.

Everything starts with HBsAg, the surface antigen: present, it means current infection; persisting past six months, chronic infection. Around it, a small panel reads history and status — anti-HBs (immunity from vaccination or recovery), anti-HBc (evidence of ever having met the virus), HBeAg and its antibody (a marker of replication phase). Two numbers then do the heavy lifting of management: HBV DNA, the viral load, measuring replication directly; and ALT, tracking liver inflammation. Their combination — with time — assigns the phase that drives treatment.

The second half of the work-up maps the liver itself. Transient elastography (FibroScan) measures stiffness — a validated proxy for fibrosis — painlessly in minutes, and has largely displaced biopsy for staging; blood indices such as FIB-4 serve where elastography is unavailable; biopsy is reserved for genuinely ambiguous cases. Ultrasound examines texture and — crucially — screens for tumours; with the blood marker alpha-fetoprotein it forms the six-monthly surveillance pair for those who need it. Every new diagnosis is also screened for the travelling companions — hepatitis D (always, and repeatedly missed where testing is not routine), hepatitis C and HIV — and for hepatitis A immunity, worth vaccinating in any chronic liver disease.

The testing net then widens beyond the patient: household members and sexual partners are tested and vaccinated; children of carrier mothers are checked; and — a scenario worth naming because it is so preventable — anyone about to receive chemotherapy, rituximab or other strong immunosuppression is screened for HBV first, because reactivation of silent infection under immunosuppression is dangerous and, with prophylactic antivirals, almost entirely avoidable.

How often does all this monitoring actually happen? For untreated carriers, typically every six to twelve months — bloods, and ultrasound where surveillance criteria apply; for treated patients, blood checks every three to six months once stable; for cirrhosis, the six-monthly rhythm is fixed. It is a light calendar by chronic-disease standards — two to four appointments a year — and telemedicine now carries much of it in many systems. The pattern to avoid has a name in every hepatology clinic: the patient who felt well, drifted for five years, and returned with a complication that six-monthly ultrasound was designed to pre-empt.

The values that recur in every hepatitis B clinic letter, and why each is watched.

The complications that give hepatitis B its weight are two. Cirrhosis develops in a minority of carriers after decades of immune-active disease, arriving silently and staying compensated — often for years — before any of its failures show. When decompensation comes, it wears the classic faces: ascites, variceal bleeding, encephalopathy, jaundice, and the muscle wasting and frailty that accompany them. Hepatocellular carcinoma is the second destination, and hepatitis B’s particular menace is that it can arrive WITHOUT cirrhosis — the viral DNA integrates into liver-cell genomes and can drive cancer directly — which is why surveillance criteria in HBV include non-cirrhotic groups (defined by age, sex, family history and regional guidelines) that other liver diseases exempt.

The detours are rarer but worth naming. Hepatitis D superinfection can turn a stable carrier into a rapidly progressive case — the single strongest reason every carrier should be tested for it once, and newly available therapy (bulevirtide) makes finding it actionable. Reactivation under immunosuppression — chemotherapy, rituximab, transplant drugs — can cause severe flares in patients whose infection seemed resolved; screening-plus-prophylaxis prevents it almost entirely — a checklist item, not a dilemma. Extrahepatic complications — certain kidney diseases and vasculitides — are uncommon immune side-plots that respond to antiviral control. And acute-on-chronic flares, whether spontaneous or after stopping treatment abruptly, can occasionally be severe enough to threaten liver failure: the practical rule for patients is simply never to stop antivirals without their specialist’s plan.

Hepatitis B is preventable to a degree almost no other chronic disease matches. The hepatitis B vaccine — three doses, safe, effective, in use since the 1980s — produces protective immunity in the vast majority, and the birth-dose strategy interrupts the mother-to-child route that fills the world’s carrier pool: WHO targets every newborn receiving a first dose within twenty-four hours. For families of carriers the checklist is short and complete: test household members and partners; vaccinate the non-immune; for pregnancies, check the mother’s viral load in the third trimester, add an antiviral where it is high, and give the newborn vaccine (plus immunoglobulin where indicated) on day one. Executed, that checklist ends transmission in a family in one generation.

For the person who already carries the virus, prevention means protecting the liver from everything else. Alcohol multiplies HBV’s damage and deserves honesty rather than vagueness: with significant fibrosis the safe amount is none, and with mild disease less is measurably better. Weight, diabetes and fatty liver add a second driver of scarring worth treating in parallel. Hepatitis A vaccination removes a needless acute risk. Herbal and traditional remedies with liver toxicity are worth listing with a doctor by name. Household hygiene is a matter of not sharing razors and toothbrushes and covering wounds — no more. And the two system-level protections: telling every new doctor about the infection before immunosuppressive treatment is prescribed, and keeping the monitoring appointments even in the phases when no treatment is needed — because the phases change, and the change is silent.

Coffee, of all things, earns its footnote here as it does on this platform’s cirrhosis page: consistent observational evidence associates regular consumption with slower fibrosis progression across liver diseases, and guidelines have begun cautiously saying so. It is an association, not a prescription — but for a disease whose lifestyle rules are mostly prohibitions, one permissive line is worth reporting accurately.

Modern first-line treatment is a once-daily tablet from a short list: entecavir, tenofovir disoproxil fumarate, or tenofovir alafenamide. All three suppress viral replication to undetectable in the vast majority who take them consistently, carry a high barrier to resistance, and are safe over many years; the choice between them turns on kidneys, bones, pregnancy plans and prior exposure history. What they achieve is control, not eradication: DNA becomes undetectable, ALT normalises, fibrosis stops progressing and — shown repeatedly in long-term cohorts — often regresses, while cancer risk falls substantially though not to zero (hence surveillance continues). What they rarely achieve is HBsAg loss, the “functional cure”, which occurs in only a small percentage even over long therapy — the gap the next generation of drugs in trials aims to close.

Who is treated follows the phases: active hepatitis (raised ALT with significant DNA) in either e-antigen state; anyone with cirrhosis, at any detectable load; special situations including pregnancy with high viral load (third-trimester tenofovir to protect the newborn), immunosuppression (prophylaxis against reactivation), and co-infections on their own rules. Who is monitored instead: the immune-tolerant young and the genuinely inactive carrier — with the emphasis that monitored means scheduled, not forgotten, since phases shift silently. Treatment duration is typically long-term: e-antigen-positive patients who seroconvert can sometimes consolidate and stop under supervision; e-antigen-negative disease usually means indefinite therapy, because stopping relapses more often than not — and stopping is never a private decision, given flare risk. Adherence deserves its unglamorous paragraph: these tablets forgive little — resistance and rebound both exploit missed weeks — and the practical toolkit is the usual one: a fixed daily anchor (with brushing teeth, with a prayer, with a phone alarm), a travel buffer in the luggage, a renewal reminder before the pack runs dry, and honesty with the clinic when supply or cost falters, since programmes and generics exist in most countries precisely for that conversation.

Pegylated interferon, a one-year injectable course, remains an option for selected younger patients who prefer a finite treatment and accept its side effects for a modestly higher chance of durable off-treatment control. Hepatitis D co-infection now has dedicated therapy (bulevirtide) in a growing number of countries. And the pipeline — RNA interference agents, capsid inhibitors, therapeutic vaccines — is aimed squarely at functional cure; a carrier reading trial news is right to be interested and right to be patient.

Living with hepatitis B, practically: the tablets travel well (a doctor’s letter smooths border questions); alcohol rules follow the liver’s state, not a universal ban — though with fibrosis the honest number is zero; diet needs no special regime beyond the metabolic common sense every liver appreciates; sport, work and study carry no restrictions, and disclosure duties vary by country and profession — worth one informed conversation rather than assumption. Pregnancy is fully compatible with the infection under the standard protocol; breastfeeding is safe with newborn immunisation. Stigma, still real in many communities, runs far ahead of the science: a treated, monitored carrier poses no risk through any ordinary contact, and saying so plainly is part of care.

The global context reframes individual worry usefully: an estimated quarter-billion carriers means chronic hepatitis B is among the most ordinary serious conditions on earth — colleagues, neighbours and public figures carry it invisibly everywhere. WHO’s 2030 elimination framework (vaccination, testing, treatment scale-up) is behind schedule but moving; several high-burden countries have halved childhood carriage within a generation. A reader newly diagnosed joins, in other words, not a rare misfortune but a vast, well-mapped cohort whose management is one of public health’s genuine competences.

Liver transplantation enters the hepatitis B story at its two destinations: decompensated cirrhosis that antivirals and supportive care can no longer stabilise, and hepatocellular carcinoma within transplant criteria — where removing the whole liver treats tumour, cirrhosis and viral reservoir together and offers the best cure rates of any approach for early cancer. A third, rarer entrance is fulminant hepatitis B — acute liver failure — which runs on the emergency rules described on this platform’s acute liver failure page.

What distinguishes HBV transplantation is how completely its old problem has been solved. Recurrent infection of the graft, once nearly universal and often graft-destroying, is now prevented by antiviral therapy continued indefinitely after transplant, with hepatitis B immunoglobulin added around the operation in many protocols; recurrence has fallen to low single figures and the post-transplant outlook for hepatitis B now matches or betters the other major indications. The practical consequences for a patient: antivirals continue for life after transplant, alongside standard immunosuppression, and both belong on every future medication list unprompted.

A capability worth knowing exists in this field: grafts from donors with past (resolved or core-antibody-positive) hepatitis B are used safely under antiviral cover in many programmes, modestly widening the donor pool — an example of the informed trade-offs a transplant team will discuss openly. For international patients, the referral file mirrors the disease’s logic: full virology (HBsAg, HBeAg status, DNA history, hepatitis D result), the antiviral history with response, fibrosis staging over time, decompensation events, complete tumour imaging and AFP trend where cancer is present, and — as everywhere in living-donor programmes — the honest documentation of any proposed donor’s relationship, health and hepatitis B immunity status. The living-donor questions this platform’s legal-gate pages handle apply here unchanged — see the liver transplant and living donation guides: donors must be genuinely voluntary, medically evaluated in their own right, and lawful under the destination country’s rules.

For the treated and monitored, chronic hepatitis B has become a disease people live WITH far more often than die FROM. Long-term cohorts on modern antivirals show suppressed virus in the overwhelming majority, fibrosis regressing as often as progressing, decompensation becoming uncommon, and liver-cancer incidence falling markedly — the reason guidelines treat linkage to care, not the infection itself, as the fork in the road. Even established cirrhosis, caught compensated and treated, often holds stable for many years; and transplant outcomes for the minority who need one now sit among the best in liver medicine, the recurrence problem having been effectively retired.

The honest counterweights: functional cure remains uncommon with current drugs, so treatment is a long commitment; cancer risk falls but does not vanish, so surveillance is a permanent appointment for those who meet criteria; hepatitis D, where present and untreated, worsens every number above; and globally, the outlook gap is a testing-and-access gap — WHO estimates most carriers remain undiagnosed, and the elimination targets for 2030 are, bluntly, behind schedule. For an individual reading this page, those global sentences compress into a personal three: know your status, keep your appointments, and never let a new doctor prescribe immunosuppression without knowing about the virus. The disease rewards exactly that kind of unheroic diligence.